Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ANGLE plc ( (GB:AGL) ) has provided an announcement.
ANGLE plc announced a significant publication in Nature Genetics, highlighting the use of its Parsortix system to study the genetic diversity of circulating tumor cell (CTC) clusters. This research, conducted by Professor Nicola Aceto’s team, underscores the importance of CTC clusters in cancer progression and metastasis, revealing that these clusters are key contributors to genetic diversity and therapy resistance. The findings suggest that targeting CTC clusters could be crucial in halting cancer spread, as they are significantly more metastatic than individual CTCs, which has profound implications for cancer treatment strategies.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
More about ANGLE plc
ANGLE plc is a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company offers the Parsortix PC1 System, which is FDA cleared and designed for harvesting CTCs from blood samples for comprehensive downstream analysis. ANGLE focuses on clinical services and diagnostic products, with its offerings supported by over 100 peer-reviewed publications.
Average Trading Volume: 1,202,369
Technical Sentiment Signal: Sell
Current Market Cap: £20.16M
For an in-depth examination of AGL stock, go to TipRanks’ Overview page.